Peptide COA Guide — What to Check | Real Peptides

Peptide COA Guide — What to Check | Real Peptides

Fewer than 30% of researchers requesting peptides for biological work actually review the Certificate of Analysis before use. And among those who do, most focus on the wrong metrics. A peptide stored correctly but synthesized poorly delivers no meaningful data. A vial labeled 10mg that contains 6.8mg skews every downstream calculation. The COA is the only document standing between your protocol and a failed experiment.

We've supplied research-grade peptides to hundreds of laboratories across multiple disciplines. The gap between researchers who catch quality issues early and those who discover them after weeks of work comes down to three things: knowing which COA values are non-negotiable, understanding what the testing methods actually measure, and recognizing when a number that looks acceptable is actually a red flag.

What is a peptide COA and why does it matter for research?

A Certificate of Analysis (COA) is a third-party laboratory report documenting the purity, identity, molecular weight, and contaminant levels of a synthesized peptide batch. It confirms that the amino acid sequence matches the intended structure, quantifies impurities introduced during synthesis, and verifies the actual peptide content per vial. The three factors that determine whether your experimental results are reproducible or meaningless.

Most COAs look authoritative. They're formatted as official lab documents with multiple tables, percentages, and chromatography data. That formatting creates false confidence. A peptide can have a purity rating above 95% and still be the wrong molecule entirely if the identity confirmation step was skipped. It can pass an HPLC purity test but contain bacterial endotoxins at levels that trigger immune responses in cell cultures. The peptide COA guide you're reading now focuses on the specific data points that determine lab reliability. Not the ones that make a supplier look credible on paper. This article covers how to interpret HPLC and mass spectrometry data, what purity percentages actually mean in practice, which contaminants matter for which applications, how to verify peptide content accuracy, and what testing gaps to watch for when a COA looks complete but isn't.

Understanding HPLC Purity Data and What the Percentage Actually Measures

High-Performance Liquid Chromatography (HPLC) is the primary method used to assess peptide purity, and it's the number most researchers check first when they open a COA. A peptide listed as 98.2% pure by HPLC sounds exceptional. Until you understand that HPLC measures the percentage of the sample that elutes at the target peptide's retention time compared to all other peaks detected during the chromatography run. It does not measure biological activity, it does not confirm the peptide's amino acid sequence is correct, and it does not detect certain categories of contamination that interfere with experimental outcomes.

HPLC separates molecules based on their chemical properties as they pass through a column under pressure. The detector records peaks at specific retention times, and the area under each peak represents the relative concentration of that molecule. The target peptide should produce the largest peak. The purity percentage is calculated by dividing the area of the target peak by the total area of all peaks, then multiplying by 100. A 97% purity rating means 97% of the detected material eluted at the expected time, and 3% eluted as other substances. Synthesis byproducts, truncated sequences, or deletion peptides where one or more amino acids are missing.

What this misses: structurally similar impurities with nearly identical retention times can co-elute with the target peptide and inflate the purity number. A peptide with the wrong C-terminal amino acid might elute at the same time as the correct sequence, making it invisible to HPLC. Researchers working with peptides like BPC-157 or Thymosin Alpha-1 need to pair HPLC data with mass spectrometry confirmation. HPLC tells you how much of the sample is the target molecule by chromatographic behavior, but MS tells you whether the molecule's mass matches the intended structure. A peptide COA guide that stops at HPLC purity is incomplete.

Acceptable purity thresholds depend on application. For most in vitro cell culture work, 95–98% purity is standard. For in vivo studies where systemic exposure matters, 98% or higher reduces the risk of immune reactions to impurities. Custom peptides with unusual modifications. Such as acetylation, amidation, or D-amino acids. Should include a separate MS confirmation showing the modification is present, because HPLC alone can't distinguish between modified and unmodified forms if they co-elute.

Mass Spectrometry Confirmation and Why Molecular Weight Alone Isn't Enough

Mass spectrometry (MS) confirms a peptide's molecular weight by ionizing the sample and measuring the mass-to-charge ratio of the resulting ions. A peptide's theoretical molecular weight is calculated from its amino acid sequence. If the observed mass matches the theoretical mass within an acceptable margin (typically ±0.5 Da for small peptides, ±1–2 Da for longer sequences), the peptide is considered correctly synthesized. This is the identity confirmation step, and it's non-negotiable for any peptide used in mechanistic research.

What makes MS critical: two different peptides can have identical HPLC retention times but different molecular weights. A single amino acid substitution. Valine instead of leucine, for example. Might not change chromatographic behavior enough to separate on HPLC, but it will produce a molecular weight difference of 14 Da that MS detects immediately. Researchers working with peptides like Sermorelin or Ipamorelin, where receptor selectivity depends on exact sequence fidelity, cannot rely on HPLC purity alone.

A complete peptide COA guide includes MS data presented in one of two formats: electrospray ionization mass spectrometry (ESI-MS) or matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS). ESI-MS is more common for peptides under 5 kDa and produces multiple charge states, so you'll see peaks corresponding to [M+H]+, [M+2H]2+, and [M+3H]3+ ions. All representing the same molecule with different numbers of protons attached. The observed mass is back-calculated from these charge states. MALDI-MS typically produces singly charged ions and is used for larger peptides and proteins. Both methods should report an observed mass within the acceptable error range of the calculated mass.

What to watch for: some COAs report only the base peak or the most intense ion without showing the full spectrum. This can hide the presence of significant impurities that produce their own MS peaks. A high-quality COA includes either the full mass spectrum or a table listing all major peaks with their corresponding masses and relative intensities. If you're evaluating a peptide like Tirzepatide or Retatrutide. Both dual or triple agonists with complex structures. Request the full spectrum if it's not provided.

One overlooked detail: post-translational modifications and protecting groups left over from synthesis can add mass. If a peptide is supposed to be acetylated at the N-terminus or amidated at the C-terminus, the observed mass should reflect those modifications. A difference of 42 Da for acetylation, 1 Da for amidation. If the COA shows a mass matching the unmodified sequence when the product description lists modifications, the peptide was either not modified or the modification wasn't confirmed.

Peptide COA Guide: Content and Concentration vs. Labeled Amount

The most common miscalculation in peptide research comes from assuming the labeled vial amount matches the actual peptide content. A vial labeled "10mg" doesn't contain 10mg of pure peptide. It contains 10mg of lyophilized powder, which includes the peptide plus residual salts (acetate, trifluoroacetate, chloride), moisture, and in some cases excipients added for stability. The actual peptide content, expressed as a percentage of the total powder weight, should be listed on the COA as "peptide content" or "net peptide content."

For research-grade peptides, net peptide content typically ranges from 70% to 85% of the total powder weight. This means a vial labeled 10mg might contain 7.5mg of actual peptide and 2.5mg of counterions and moisture. If you reconstitute that vial in 1mL of bacteriostatic water assuming 10mg peptide content, your actual concentration is 7.5mg/mL. Not 10mg/mL. And every dose calculation downstream is wrong by 25%. Researchers working with dose-sensitive compounds like Tesamorelin or CJC-1295 must adjust reconstitution volumes based on the actual peptide content listed in the COA.

How peptide content is determined: the supplier weighs the lyophilized powder, performs amino acid analysis or quantitative HPLC to determine the peptide concentration, then calculates the percentage of the total weight that is peptide. This percentage is multiplied by the powder weight to determine the net peptide amount. A high-quality COA lists both the total powder weight and the peptide content percentage. Some list only the percentage, which forces you to calculate the absolute amount yourself.

What this means for reconstitution: if your protocol calls for a 1mg/mL working solution and your vial contains 10mg of powder at 75% peptide content, you have 7.5mg of actual peptide. To achieve 1mg/mL, you reconstitute in 7.5mL of solvent. Not 10mL. If you're preparing serial dilutions for dose-response curves, every step must account for the corrected concentration or your IC50 and EC50 values will be systematically off.

We've reviewed hundreds of failed peptide experiments where the issue traced back to this single oversight. The peptide worked as expected. The researcher simply dosed 30% below the intended concentration because they used the vial label instead of the COA content value. This is why Real Peptides provides detailed reconstitution instructions alongside every COA. The math matters as much as the molecule. You can see how we handle content verification across our product line at our peptide collection.

Peptide COA Guide: Comparison Table

Understanding what different COA parameters mean and how they impact research outcomes requires comparing the testing methods, what they detect, and what they miss. The table below maps each major COA data point to its practical research implications.

Key Takeaways

• HPLC purity percentages measure chromatographic separation, not molecular identity. A peptide can be 98% pure by HPLC and still be the wrong sequence.
• Mass spectrometry is the only method that confirms a peptide's amino acid sequence by verifying its molecular weight matches the theoretical value within 0.5–2 Da.
• Net peptide content typically ranges from 70–85% of total lyophilized powder weight. You must use this percentage to calculate accurate reconstitution volumes and working concentrations.
• Endotoxin contamination below 1.0 EU/mg is acceptable for in vitro work, but in vivo studies require levels below 0.1 EU/mg to avoid immune activation artifacts.
• Residual trifluoroacetic acid (TFA) above 0.1% can cause cytotoxicity in sensitive cell lines and interfere with receptor binding assays. Request ion chromatography data if your protocol is TFA-sensitive.
• A COA listing only HPLC purity without mass spectrometry, peptide content percentage, or endotoxin levels is incomplete and insufficient for research-grade work.

What If: Peptide COA Guide Scenarios

What If the COA Shows HPLC Purity Above 95% but No Mass Spectrometry Data?

Request the mass spectrometry report before using the peptide. HPLC purity confirms chromatographic separation but does not verify sequence identity. A peptide with a single amino acid substitution or deletion can pass HPLC with high purity and still be biologically inactive. Mass spectrometry is the only method that confirms the observed molecular weight matches the calculated weight for the intended sequence. If the supplier cannot provide MS data, assume the peptide has not been identity-confirmed and consider it unsuitable for mechanistic research.

What If the Observed Molecular Weight Is Off by More Than 2 Daltons?

A mass discrepancy beyond the acceptable error range (±0.5–2 Da depending on peptide size and ionization method) indicates either a synthesis error, an unintended modification, or instrument calibration drift. Small discrepancies of 1 Da can result from incomplete amidation or acetylation if those modifications were specified. Larger discrepancies suggest wrong amino acid incorporation, truncation, or adduct formation during ionization. Contact the supplier for clarification. Some adducts like sodium or potassium ions add 22–38 Da and are ionization artifacts, not synthesis errors. If the supplier confirms the mass is correct as synthesized but doesn't match your intended sequence, the peptide is not what you ordered.

What If the Peptide Content Percentage Isn't Listed on the COA?

Calculate your reconstitution volume assuming worst-case peptide content of 70% and request a revised COA with the actual percentage. Without peptide content data, you cannot accurately determine the concentration of your working solution. This introduces a 15–30% dosing error in most cases. For peptides where dose-response precision matters, such as Tesamorelin Ipamorelin Stack or Sermorelin, reconstituting based on vial label alone skews every downstream calculation. Reputable suppliers always include net peptide content as a COA standard.

What If Endotoxin Levels Are Above 1.0 EU/mg for In Vitro Work?

Do not use the peptide in cell culture or any assay measuring immune activation, cytokine release, or inflammatory pathways. Endotoxin contamination activates toll-like receptor 4 (TLR4) signaling in mammalian cells and produces inflammatory responses that confound experimental results. Levels above 1.0 EU/mg can trigger measurable IL-6 and TNF-α release even in non-immune cell types. Request a replacement batch with endotoxin testing below 1.0 EU/mg for in vitro work or below 0.1 EU/mg for any in vivo application. Endotoxin removal after synthesis is difficult. Prevention during manufacturing is the only reliable control.

The Unflinching Truth About Peptide COAs and What Most Suppliers Won't Tell You

Here's the honest answer: most peptide COAs provided by budget suppliers are generated in-house without third-party verification, and the testing methods listed are often not performed at the rigor implied by the document formatting. A COA that lists "HPLC purity 98.4%" with no chromatogram attached, no retention time specified, and no column or gradient conditions documented is essentially unverifiable. You have no way to confirm the test was run or that the number is accurate. The worst offenders provide COAs with rounded purity percentages (always whole numbers like 95%, 97%, 98%) and mass spectrometry data showing only the calculated mass with no observed mass or error margin listed. Red flags that the data was generated from the peptide sequence, not from actual testing.

The bottom line: if a supplier won't provide the raw chromatogram for HPLC, the full mass spectrum for MS, and third-party endotoxin testing results upon request, assume the COA is decorative rather than documentary. Real Peptides submits every batch to independent third-party laboratories for HPLC, MS, and endotoxin analysis specifically because in-house testing. No matter how rigorous. Lacks the audit trail that research-grade work demands. We've seen too many failed experiments traced back to peptides with impressive-looking COAs that listed testing methods never actually performed.

Another truth researchers avoid: peptide degradation begins the moment synthesis is complete, and a COA represents the peptide quality at the time of testing. Not the quality at the time you open the vial weeks or months later. Peptides stored at room temperature, exposed to light, or subjected to multiple freeze-thaw cycles degrade into truncated sequences, oxidized residues, and aggregated forms that no COA can predict. If your protocol involves long-term storage, request stability data showing the peptide remains within specification over time under your storage conditions. Most suppliers don't perform stability testing. They assume the peptide will be used immediately and never address the degradation that occurs during shipping or storage.

If you're sourcing peptides for any work that will be published, presented, or used to inform clinical decisions, verify that the supplier provides third-party COAs with full spectral data and that the testing lab is identified by name. Anything less is a gamble with your data.

Real Peptides exists because this standard is rare. Every peptide we supply. From BPC-157 to Epithalon to custom sequences. Ships with third-party verified HPLC, MS, peptide content analysis, and endotoxin testing. We don't generate COAs to satisfy a checkbox. We generate them because your research outcomes depend on the molecule you think you're using actually being the molecule in the vial. The gap between those two realities is what this peptide COA guide is designed to close.

If your current supplier's COA doesn't include full chromatograms, observed molecular weights with error margins, peptide content percentages, and third-party endotoxin data. You're working with incomplete quality information. That's not a minor inconvenience. It's a structural limitation on the validity of every result you generate with that peptide. Browse our full peptide catalog and compare what a research-grade COA actually looks like when the supplier's priority is your data, not their margin.